Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7471 to 7485 of 8314 results

  1. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued Reference number: GID-TA10933

    Technology appraisal guidance
    Discontinued

  3. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  4. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued Reference number: GID-TA10906

    Technology appraisal guidance
    Discontinued

  6. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  7. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  8. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  9. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    Discontinued Reference number: GID-TA10728

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

    Technology appraisal guidance
    Discontinued

  11. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    In development Reference number: GID-TA11128 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  13. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  14. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  15. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued